Aeterna Zentaris Inc. (TSE:AEZS) has released an update.
Aeterna Zentaris Inc. has successfully finished enrolling participants for its pivotal Phase 3 DETECT-trial, assessing macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency, with results expected in the upcoming quarters. Financially, the company is well-positioned with $34.0 million in cash to support operations into 2025. Additionally, a strategic all-stock merger with Ceapro Inc. is anticipated to be finalized in the second quarter of 2024.
For further insights into TSE:AEZS stock, check out TipRanks’ Stock Analysis page.
